Nymox Pharmaceutical Corporation  

(Public, NASDAQ:NYMX)   Watch this stock  
Find more results for PAUL MCDONALD, ESQ�
-0.02 (-0.62%)
Oct 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.12 - 3.42
52 week 0.33 - 5.55
Open 3.22
Vol / Avg. 202,285.00/559,155.00
Mkt cap 120.86M
P/E     -
Div/yield     -
EPS -0.62
Shares 37.80M
Beta 1.26
Inst. own 3%

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -41697.78% -155.76%
Operating margin -41595.84% -160.19%
EBITD margin - -159.96%
Return on average assets -8795.63% -384.61%
Return on average equity - -
Employees 24 -
CDP Score - -


9900 Cavendish Blvd. Suite 306
+1-800-9369669 (Phone)
+1-514-3322227 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company has two subsidiaries: one wholly owned subsidiary Nymox Corporation and the other a majority owned subsidiary Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development and some of the manufacturing for NicAlert and TobacAlert.

Officers and directors

Paul Averback M.D. Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Erik Danielsen Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Jack Gemmell Chief Information Officer, General Counsel, Director
Age: 63
Bio & Compensation  - Reuters
Brian Doyle Senior Manager - Global Sales and Marketing
Age: 60
Bio & Compensation  - Reuters
Roger Guy M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Randall Lanham Esq. Independent Director
Age: 51
Bio & Compensation  - Reuters
Paul F. McDonald Independent Director
Age: 89
Bio & Compensation  - Reuters
David Morse Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters